Fennec Pharmaceuticals Inc
NASDAQ:FENC
Balance Sheet
Balance Sheet Decomposition
Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc
Balance Sheet
Fennec Pharmaceuticals Inc
| Jun-2003 | Dec-2004 | Dec-2005 | Dec-2006 | Dec-2007 | Dec-2008 | Dec-2009 | Dec-2010 | Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||||||||
| Cash & Cash Equivalents |
2
|
17
|
12
|
6
|
16
|
5
|
1
|
6
|
5
|
2
|
2
|
2
|
1
|
4
|
28
|
23
|
14
|
30
|
21
|
24
|
13
|
25
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
|
| Cash Equivalents |
2
|
17
|
12
|
6
|
16
|
5
|
1
|
6
|
5
|
2
|
2
|
2
|
1
|
4
|
28
|
23
|
14
|
30
|
21
|
24
|
12
|
25
|
|
| Short-Term Investments |
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
9
|
13
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
9
|
13
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
1
|
|
| Other Current Assets |
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
3
|
4
|
|
| Total Current Assets |
3
|
18
|
13
|
6
|
17
|
6
|
1
|
6
|
5
|
2
|
2
|
2
|
1
|
4
|
28
|
23
|
14
|
31
|
22
|
27
|
27
|
44
|
|
| PP&E Net |
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Intangible Assets |
22
|
20
|
14
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Total Assets |
26
N/A
|
39
+52%
|
28
-27%
|
7
-77%
|
17
+160%
|
6
-65%
|
1
-86%
|
6
+622%
|
5
-11%
|
2
-56%
|
2
-26%
|
2
+35%
|
1
-57%
|
4
+289%
|
28
+615%
|
23
-19%
|
14
-38%
|
31
+122%
|
22
-29%
|
27
+20%
|
27
0%
|
45
+67%
|
|
| Liabilities | |||||||||||||||||||||||
| Accounts Payable |
0
|
0
|
1
|
2
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
2
|
1
|
2
|
4
|
3
|
|
| Accrued Liabilities |
0
|
0
|
1
|
3
|
2
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
2
|
4
|
3
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
1
|
2
|
0
|
0
|
0
|
0
|
0
|
10
|
5
|
7
|
3
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
1
|
2
|
3
|
5
|
2
|
2
|
0
|
11
|
5
|
7
|
3
|
2
|
0
|
0
|
2
|
2
|
2
|
2
|
2
|
5
|
8
|
7
|
|
| Long-Term Debt |
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
25
|
30
|
18
|
|
| Deferred Income Tax |
8
|
7
|
5
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
26
|
|
| Total Liabilities |
10
N/A
|
9
-9%
|
8
-11%
|
5
-36%
|
3
-43%
|
3
-2%
|
0
-86%
|
11
+2 440%
|
5
-50%
|
7
+34%
|
3
-56%
|
2
-45%
|
0
-73%
|
0
-15%
|
2
+310%
|
2
N/A
|
2
+38%
|
2
+4%
|
7
+183%
|
30
+344%
|
38
+30%
|
51
+32%
|
|
| Equity | |||||||||||||||||||||||
| Common Stock |
19
|
41
|
41
|
47
|
65
|
65
|
65
|
65
|
66
|
66
|
67
|
69
|
69
|
75
|
103
|
106
|
106
|
141
|
141
|
143
|
144
|
146
|
|
| Retained Earnings |
17
|
38
|
52
|
71
|
84
|
98
|
101
|
109
|
105
|
111
|
109
|
111
|
112
|
114
|
121
|
131
|
144
|
162
|
179
|
203
|
219
|
220
|
|
| Additional Paid In Capital |
13
|
27
|
25
|
25
|
32
|
35
|
35
|
38
|
38
|
38
|
39
|
42
|
42
|
42
|
44
|
45
|
48
|
49
|
53
|
57
|
62
|
67
|
|
| Other Equity |
0
|
0
|
6
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Total Equity |
15
N/A
|
30
+94%
|
20
-32%
|
1
-94%
|
14
+1 014%
|
3
-78%
|
0
-87%
|
5
N/A
|
0
+98%
|
5
-4 033%
|
1
+71%
|
1
N/A
|
1
-10%
|
4
+549%
|
27
+650%
|
21
-20%
|
12
-44%
|
29
+145%
|
16
-46%
|
3
N/A
|
12
-352%
|
6
+49%
|
|
| Total Liabilities & Equity |
26
N/A
|
39
+52%
|
28
-27%
|
7
-77%
|
17
+160%
|
6
-65%
|
1
-86%
|
6
+622%
|
5
-11%
|
2
-56%
|
2
-26%
|
2
+35%
|
1
-57%
|
4
+289%
|
28
+615%
|
23
-19%
|
14
-38%
|
31
+122%
|
22
-29%
|
27
+20%
|
27
0%
|
45
+67%
|
|
| Shares Outstanding | |||||||||||||||||||||||
| Common Shares Outstanding |
0
|
1
|
1
|
1
|
2
|
2
|
7
|
7
|
8
|
8
|
10
|
11
|
11
|
14
|
18
|
20
|
20
|
26
|
26
|
26
|
27
|
28
|
|